Recovery of drug-resistant influenza virus from immunocompromised patients: A case series

被引:202
作者
Ison, MG
Gubareva, LV
Atmar, RL
Treanor, J
Hayden, FG
机构
[1] Univ Virginia Hlth Syst, Div Infect Dis & Int Hlth, Dept Med, Charlottesville, VA 22908 USA
[2] Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA
[3] Baylor Coll Med, Dept Med, Houston, TX USA
[4] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX USA
[5] Univ Rochester, Div Infect Dis, Rochester, NY USA
关键词
D O I
10.1086/500465
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Influenza virus with resistance to antiviral drugs emerges with increased frequency in immunocompromised patients and can limit the benefit of M2 and neuraminidase (NA) inhibitors. We document 3 cases of influenza in severely immunocompromised patients from whom virus variants with molecular markers of resistance to anti-influenza drugs were recovered. Virus variants recovered from 2 patients had mutations in the M2, NA (with a previously recognized Glu119Val NA substitution), and hemagglutinin genes. We describe a novel Asp198Asn NA mutation in an influenza B virus and its decreased susceptibility to both oseltamivir and zanamivir.
引用
收藏
页码:760 / 764
页数:5
相关论文
共 16 条
[1]   Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an Immunocompromised patient [J].
Boivin, G ;
Goyette, N ;
Bernatchez, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :E23-E25
[2]   Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern [J].
Bright, RA ;
Medina, MJ ;
Xu, XY ;
Perez-Oronoz, G ;
Wallis, TR ;
Davis, XHM ;
Povinelli, L ;
Cox, NJ ;
Klimov, AI .
LANCET, 2005, 366 (9492) :1175-1181
[3]  
BRIGHT RA, 2006, JAMA
[4]   Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells [J].
Govorkova, EA ;
Fang, HB ;
Tan, M ;
Webster, RG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4855-4863
[5]   Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors [J].
Gubareva, LV .
VIRUS RESEARCH, 2004, 103 (1-2) :199-203
[6]   A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site [J].
Gubareva, LV ;
Nedyalkova, MS ;
Novikov, DV ;
Murti, KG ;
Hoffmann, E ;
Hayden, FG .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :2683-2692
[7]   Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus [J].
Gubareva, LV ;
Matrosovich, MN ;
Brenner, MK ;
Bethell, RC ;
Webster, RG .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (05) :1257-1262
[8]   Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en [J].
Gubareva, LV ;
Bethell, R ;
Hart, GJ ;
Murti, KG ;
Penn, CR ;
Webster, RG .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1818-1827
[9]   Viral infections in immunocompromised patients: what's new with respiratory viruses? [J].
Ison, MG ;
Hayden, FG .
CURRENT OPINION IN INFECTIOUS DISEASES, 2002, 15 (04) :355-367
[10]   Resistant influenza A viruses in children treated with oseltarnivir: descriptive study [J].
Kiso, M ;
Mitamura, K ;
Sakai-Tagawa, Y ;
Shiraishi, K ;
Kawakami, C ;
Kimura, K ;
Hayden, FG ;
Sugaya, N ;
Kawaoka, Y .
LANCET, 2004, 364 (9436) :759-765